A study of DoTiNurad aiming to treat hyperuricemia with CKD

Not Applicable

• Conditions: Patients with hyperuricemia whose renal function is in the GFR range of G1 to G4

• Registration Number: JPRN-jRCTs061210079
• Lead Sponsor: Wada Jun

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1) Patients with hyperuricemia aged 20 years or older at the time of providing informed consent
2) Patients who have not received treatment with uricosuric drugs within 2 weeks prior to the observation start date
3) Patients with a serum uric acid level (untreated level) 8.0 mg/dL or higher within 6 weeks prior to the observation start date
4) Patients with an estimated GFR (eGFR) 15 mL/min/1.73m2 or higher within 6 weeks prior to the observation start date

Exclusion Criteria

1) Patients with acute gouty arthritis that has not subsided
2) Patients diagnosed with urolithiasis
3) Patients with secondary hyperuricemia (tumor lysis syndrome, etc.)
4) Patients with an AST or ALT of 100 IU/L or higher
5) Patients who are pregnant, likely to be pregnant, or breastfeeding
6) Patients with a history of hypersensitivity to the ingredients contained in dotinurad preparations
7) Patients who are judged as inappropriate for this study by the principal investigator or subinvestigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified